Abstract: |
For patients with colorectal cancer metastatic to the liver alone, complete resection offers the only chance for long-term disease-free survival and cure. With the evolution of surgical technique and systemic chemotherapy options, as many as 20% can expect to live for more than 10 years after surgery, the great majority of whom are cured. At least two features of colorectal liver metastasis preclude the potential for cure. First, up to 80% of patients present with metastatic disease that is limited to the liver but not amenable to resection. And second, after resection, as many as two-thirds of patients develop recurrent disease in the liver, many of whom are not candidates for additional surgical treatment. Over the past several decades, hepatic arterial infusion chemotherapy has emerged as a treatment option that addresses both of these problems by (1) increasing the likelihood of downstaging unresectable disease so that potentially curable surgery is possible and (2) reducing the likelihood of liver recurrence after resection. This chapter will focus on the rationale for this treatment approach, the technique of delivering the therapy, and the oncologic outcomes associated with its use. © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2022. |